Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Registries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.
Allergol Select
December 2024
Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
In allergology, clinical registries fill knowledge gaps of epidemiology, mechanisms of allergic diseases, and real-world treatment outcomes. Considering the continuous rise of allergic diseases worldwide, registries become increasingly important for the optimization and harmonization of patient care. In the current review, we present four ongoing allergy-focused registries initiated in Germany.
View Article and Find Full Text PDFThe Efficacy and Safety of Non-Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Australas J Dermatol
January 2025
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Palmoplantar pustular psoriasis (PPPP), or palmoplantar pustulosis (PPP), is a type of psoriasis that affects the skin on the palms and soles. It is characterised by dermatosis and small sterile pustules and is considered a significant burden on patients' quality of life, as there is currently no gold standard treatment or cure. This network meta-analysis (NMA) compares the efficacy and safety of biologic and non-biologic medications for PPPP and PPP.
View Article and Find Full Text PDFRIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis.
Biomolecules
December 2024
Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa Street 7, 30-387 Krakow, Poland.
Melanoma cells remain resistant to chemotherapy with cisplatin (CisPt) and doxorubicin (DOX). The abnormal expression of Receptor-Interacting Protein Kinase 4 (RIPK4) in certain melanomas contributes to tumour growth through the NFκB and Wnt/β-catenin signalling pathways, which are known to regulate chemoresistance and recurrence. Despite this, the role of RIPK4 in response to chemotherapeutics in melanoma has not been reported.
View Article and Find Full Text PDFMetabolomics Analysis Using Chromatography-Mass Spectrometry to Investigate the Mechanism of Cyclosporine in the Treatment of Aplastic Anemia.
Rapid Commun Mass Spectrom
March 2025
Department of Pharmacy, The Affiliated Yixing Clinical School of Medical School of Yangzhou University, Yixing, China.
Objective: The aim of this study was to use metabolomics techniques to detect differential metabolites in the plasma of patients with aplastic anemia (AA). We explore important biomarkers and potential pathways in cyclosporine A (CsA) in the treatment of AA.
Methods: Plasma samples from five patients with AA before and after treatment and plasma samples from five healthy people were collected and analyzed by liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry.
Cyclosporine A Decreased Paclitaxel Resistance in Prostate Cancer Cells by Inhibiting MTDH Expression.
Am J Mens Health
January 2025
Department of Emergency Ward, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Article Synopsis
- The study explores how cyclosporine A (CsA) affects paclitaxel-resistant prostate cancer cells, revealing that CsA enhances the effectiveness of paclitaxel.
- CsA treatment lowers the expression of metadherin (MTDH), a protein linked to paclitaxel resistance, indicating that targeting MTDH could be a potential strategy for overcoming this resistance.
- In both lab experiments and mouse models, the findings suggest combining CsA with paclitaxel could improve treatment outcomes for prostate cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!